Investigator-Led Tavalisse Study in COVID-19 Positive for Rigel Pharmaceuticals (RIGL) - BMO
Tweet Send to a Friend
BMO Capital analyst Do Kim reiterated an Outperform rating and $8.00 price target on Rigel Pharmaceuticals (NASDAQ: RIGL) as the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
